Includes new, competitive renewal and supplemental awards.
See additional awards here: https://medicine.uiowa.edu/research/scientific-impact/deans-list-new-funding-awards
June 2024
| PI | Sponsor | Title |
|
Elissa Faro |
NIH R01 - 5 years | Can an Evidence-Based Mental Health Intervention be Implemented into Preexisting Home Visiting Programs using Implementation Facilitation? |
|
Margaret Byrne |
Merck & Company, Inc. | Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer |
|
Linda Cadaret |
GB002, Inc. | PROSERA |
|
Alejandro Comellas Freymond |
Duke University | RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) |
|
Douglas Laux |
GlaxoSmithKline LLC | Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck |
|
Lama Noureddine |
Amgen, Inc. | Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis |
|
Tahaunty Peña |
Sanofi US Services Inc. | Oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung tr |
|
Ian Thornell |
Cystic Fibrosis Foundation | Cellular contributions to HEMT |
|
Praveen Vikas |
Pfizer, Inc. | PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY |
|
Michael Wendt |
Novartis Pharmaceuticals Corporation | Impact of Hypoxia on Lipid Metabolism in Obesity-Driven Breast Cancer Progression |
|
Hanna Zembrzuska |
Novartis Pharmaceuticals Corporation | Intravenous secukinumab infusion in adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR). |
May 2024
| PI | Sponsor | Title |
|
Barry London, Contact PI |
NIH U01 - 3 years | Sex-dependent Impairment of Nitric Oxide Signaling and Mitochondrial Metabolism in Radiation-Induced Cardio-Pulmonary Dysfunction |
|
Rebecca Dodd |
Dod, CDMRP - 3 years | Targeted Therapy for MPNST Metastasis |
|
Grerk Sutamtewagul |
Kura Oncology - 3 years | Venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia |
|
Grerk Sutamtewagul |
Kura Oncology - 3 years | Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia |
|
Douglas Laux |
Regeneron Pharmaceuticals, Inc. - 3 years | REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with Cemiplimab in patients with advanced solid tumors. |
|
Sam Stephens |
Juvenile Diabetes Research Foundation International - 3 years | 201311107-FY24 SRA: Role of -cell Golgi dysfunction in Type 1 diabetes pathogenesis |
|
Christopher Strouse |
Janssen Research and Development, LLC - 2.5 years | Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma |
April 2024
| PI | Sponsor | Title |
|
Alejandro Comellas Freymond |
KUMC - 5 years | All of Us Research Program - Heartland Consortium |
|
Yousef Zakharia |
Astellas Pharma Global Development, Inc - 3 years | Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) |
|
Hanna Zembrzuska |
ImmPACT Bio USA, Inc. - 3 years | IMPT-514 in participants with active, refractory lupus nephritis and systemic lupus erythematosus |
|
Christopher Strouse |
Janssen Research & Development, Inc - 5 years | JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma |
March 2024
| PI | Sponsor | Title |
|
Sandra Blom |
NIH F31 - 3 years | GRASP55 Regulates Pancreatic Beta-cell Golgi Structure and Function During Cytokine Stress |
|
Ajit Vikram |
NIH R01 - 5 years | Glycopeptide vancomycin reshapes gut microbiota to mediate cardioprotective effects via microRNA-204 |
|
Mohammed Milhem |
Polaris Pharmaceuticals, Inc. - 5 years | Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial |
|
Antonio Sanchez |
GlaxoSmithKline, Inc. - 3 years | GSK4532990 in Adults with pre-cirrhotic Non-Alcoholic Steatohepatitis (NASH) |
|
Christopher Strouse |
Juno Therapeutics, Inc. - 4 years | BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma |
|
Grerk Sutatewagul |
Merk Sharp & Dohme, LLC - 5 years | Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) |
|
Tomohiro Tanaka |
Takeda Development Center Americas, Inc. - 5 years | Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis |
|
Yousef Zakharia |
Arsenal Biosciences - 3 years | AB-2100 in patients with recurrent advanced or metastatic clear-cell renal cell carcinoma. |
February 2024
| PI | Sponsor | Title |
|
Denice Hodgson-Zingman, Contact PI |
NIH R01 - 5 years | A New Pacing Approach for Cardiac Conditioning and Enhanced Cardioprotection |
|
Sarah Short |
NIH K01 - 5 years | Antioxidant regulation of intestinal homeostasis and disease |
|
Prajwal Dhakal |
Nerviano Medical Sciences, S.r.l. - 3 years | A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML |
|
Douglas Laux |
Hoosier Cancer Research Network, Inc. - 3 years | A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study) |
|
Saima Sharif |
PDD Investigator Services, LLC - 3 years | A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer |
January 2024
| PI | Sponsor | Title |
| Michael Tomasson | US National Science Foundation - 1 year | I-Corps: A Home-based Solution for Remote Lung Function Monitoring for Patients with Chronic Lung Disease |
|
Rami El Abiad |
Sanofi US Services Inc. - 3 years | Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants with Eosinophilic Esophagitis (EoE) |
| Umar Farooq | Janssen Research & Development, Inc. - 3 years | Global Patient Registry of Inherited Retinal Diseases |
|
Asad Javed |
IDEAYA Biosciences Inc. - 5 years | IDE196 (Darovasertib) in combination with Crizotinib versus investigator's choice of treatment as a first-line therapy in HLA-A2 negative metastatic uveal melanoma (DAR-UM-2) |
|
Douglas Laux |
Regeneron Pharmaceuticals, Inc. - 5 years | A multicenter, open-label phase 2 study of intratumoral vidutolimod (CMP-001) in combination with inravenous cemiplimabin subjects with selected types of advanced or metastatic cancer. |
|
Mohammed Milhem |
Merck Sharp & Dohme LLC - 8 years | Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma |
|
Yousef Zakharia |
Bristol-Myers Squibb Company - 5 years | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors |
See additional awards here: https://medicine.uiowa.edu/research/scientific-impact/deans-list-new-funding-awards